1Shirasaka T, Shimamoto Y, Ohshima H, et al. Development of a novel form of an oral 5-fluorouracil derivative ( S- 1 ) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators [ J ]. Anticancer Drugs, 1996, 7 : 548.
2Takeharu Y, Shigemi M, Satoshi T, et al. Safety evaluation of oral fluoropyrimidine S-1 for short-and long-term delivery in advanced gastric cancer: Analysis of 3 758 patients [J]. Cancer Chemother Pharmaeol, 2008, 61:335.
3Koizumi W, Kurihara M, Nakano S, et al. Phase Ⅱ study of S-1 , a novel oral derivative of 5-fluorouracil, in advanced gastric cancer [J]. Oncology, 2000, 58 : 191.
4Sakata Y, Ohtsu A, Horikoshi N, et al. Late Phase Ⅱ study of novel oral fluoropyrimidine anticancer drug S-1 ( 1M tegafur-0. 4M otastat potassium) in advanced gastric cancer patients [J]. EUR J Cancer, 1998, 34 : 1715.
5Koizumi W, Tanabe S, Saigenji K, et al. Phase Ⅰ/Ⅱ study of S-1 combined with cisplatin in patients with advanced gastric [J]. Br J Cancer, 2003, 8:2207.
6Ajani JA, Lee FC, Singh DA, et al. Multicenter phase Ⅱ trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma [J]. J Clin Oncol, 2006, 24 : 663.
7Jae-Lyun L, Hye JK, Yoon-Kook, et al. Phase Ⅰ/Ⅱ study of 3-week combination of S-1 and Cisplatin chemotherapy for metastatic or recurrent gastric cancer [ J ]. Cancer Chemother Pharmacol, 2008, 61 : 837.
8Inokuchi M, Yamashita T, Yamada H, et al. Phase Ⅰ/Ⅱ study of S-1 combined with irinotecan for metastatic advanced gastric cancer [J]. Br J Cancer, 2006, 94 : 1130.
9Yamaguchi K, Shimamura T, Hyodo I, et al. Phase Ⅰ/Ⅱ study of docetaxel and S-1 in patients with advanced gastric cancer [J]. Br J Cancer, 2006, 94:1803.
10Mochiki E, Ohno T, amiyama Y, et al. Phase Ⅰ/Ⅱ study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer [ J ]. Br J Cancer, 2006, 95 : 1642.
4Miller A B, Hoogstraten B, Staquet M, et al. Reporting re- suits of cancer treatment [J]. Cancer, 1981,47 ( 1 ) : 207.
5Wesolowski R, Lee C, Kim R. Is there a role for second-line chemotherapy in adavanced gastric cancer? [ J ]. Lancet Oncol, 2009,10 (9) : 903.
6M Malet-Martino, R Martino. Clinical studies of three oral prodrugs of 5-Fluorouracil( Capecitabine, UFT, S-1 ) : a re- view [J]. The oncologist, 2002,7 ( 4 ) : 288.
7Koizumi W. S-1 plus cisplatin vel - us S-1 alone for first line treatment of advanced gastric cancer. ( SPIRITS tri- al) :a phasem trial[J]. Lancet Oncol,2008,9(3) :215.
8Koizumi W, Kurihara M, Nakano S, et al. Phase 11 study of S-I ,a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Stud- y Group[ J]. Oncology,2000,58 (3) : 191.
9Ajani JA, Rodriquez W, Bodoky G, et al. Muhlcenter phase llI comparison of cisplatin/S-1 with cisplatin/infu-sional fluoronracil in advanced gastric or gastroesophageal adeno- carcinoma study : the FLAGS trial [ J ]. J Clin Oncol, 2010, 28(9) :1547.
10Fuse N, Fukuda H, Yamada Y, et al. Updated results of ran- domized phase m study of 5-fluorouracil alone versus combi- nation of irinotecan and cisplatin versus S-1 alone in ad- vanced gastric cancer ( JCOG 9912 ) [J]. J Clin Oncol ( Meeting Abstracts) ,2009,27 (15s) :4514.
